ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of Calcipotriol Plus Hydrocortisone Ointment Compared With Tacalcitol Ointment in Patients With Psoriasis on the Face and Skin Folds

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00640822
Recruitment Status : Completed
First Posted : March 21, 2008
Results First Posted : December 21, 2010
Last Update Posted : April 29, 2015
Sponsor:
Information provided by (Responsible Party):
LEO Pharma

Brief Summary:
There are few therapies suitable for the treatment of psoriasis on the face and skin folds. As these areas are sensitive, irritation and other adverse reactions are more common than elsewhere on the body. The purpose of the study is to compare the efficacy and safety of once daily treatment for up to 8 weeks of an ointment containing calcipotriol 25 mcg/g plus hydrocortisone 10 mg/g with tacalcitol 4 mcg/g ointment and the ointment vehicle alone in patients with psoriasis vulgaris on the face and on the intertriginous ares

Condition or disease Intervention/treatment Phase
Psoriasis Vulgaris Drug: Calcipotriol plus hydrocortisone ointment vehicle Drug: Tacalcitol Ointment Drug: Calcipotriol plus hydrocortisone ointment Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 782 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Investigator)
Primary Purpose: Treatment
Official Title: A Phase 3 Study Comparing an Ointment Containing Calcipotriol 25 mcg/g Plus Hydrocortisone 10 mg g With Tacalcitol 4 mcg/g Ointment and the Ointment Vehicle Alone, All Applied Once Daily in the Treatment of Psoriasis Vulgaris on the Face and on the Intertriginous Areas
Study Start Date : February 2008
Actual Primary Completion Date : June 2009
Actual Study Completion Date : July 2009


Arm Intervention/treatment
Experimental: Calcipotriol plus Hydrocortisone ointment
Calcipotriol plus Hydrocortisone ointment once daily for up to 8 weeks
Drug: Calcipotriol plus hydrocortisone ointment
Once daily application for up to 8 weeks
Active Comparator: Tacalcitol
Tacalcitol once daily for up to 8 weeks
Drug: Tacalcitol Ointment
Once daily application for up to 8 weeks
Placebo Comparator: Calcipotriol plus Hydrocortisone ointment vehicle
Calcipotriol plus Hydrocortisone ointment vehicle once daily for up to 8 weeks
Drug: Calcipotriol plus hydrocortisone ointment vehicle
Once daily application for up to 8 weeks



Primary Outcome Measures :
  1. Subjects With Controlled Disease According to the Investigator Assessment of the Face at Week 8 [ Time Frame: Week 8 ]

Secondary Outcome Measures :
  1. Overall Disease Severity of the Face According to the Investigator's Assessment [ Time Frame: Week 4 ]
  2. Total Sign Score of the Face [ Time Frame: Week 8 ]
  3. Severity Scores for Redness, Thickness and Scaliness of the Face [ Time Frame: Week 8 ]
  4. Overall Disease Severity of the Intertriginous Areas According to the Investigator's Assessment [ Time Frame: Week 8 ]
  5. Total Sign Score of the Intertriginous Areas [ Time Frame: Week 8 ]
  6. Patients With Relapse During the Study and Time to Relapse [ Time Frame: Week 8-16 ]
  7. Patients With Rebound During the Study [ Time Frame: Week 8-16 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Clinical diagnosis of psoriasis vulgaris involving the face
  • Clinical signs of psoriasis vulgaris on the trunk and/or the limbs, or earlier diagnosed with psoriasis vulgaris on the trunk and/or the limbs
  • An extent of psoriatic involvement of the face of at least 10 cm2 (the sum of all facial lesions)
  • Treatment areas (the face and the intertriginous areas) amenable to topical treatment with a maximum of 10 g of ointment per day
  • Disease severity graded as mild, moderate, severe or very severe according to the investigator's global assessment of disease severity of the face

Exclusion Criteria:

  • Systemic treatments with all other therapies than biologicals, with a potential effect on psoriasis vulgaris (e.g., corticosteroids, vitamin D analogues, retinoids, immunosuppressants) within the 4-week period prior to randomisation
  • Systemic use of biological treatments, whether marketed or not, directed against or with a potential effect on psoriasis vulgaris (e.g., alefacept, efalizumab, etanercept, infliximab, adalimumab) within 3 months prior to randomisation
  • PUVA therapy or Grenz ray therapy within the 4-week period prior to randomisation
  • UVB therapy within the 2-week period prior to randomisation
  • Topical treatment of the face and the intertriginous areas within the 2-week period prior to randomisation (use of emollients is allowed on treatment areas during this 2-week period, but not during the study)
  • Topical treatment with very potent WHO group IV corticosteroids within the 2-week period prior to randomisation
  • Initiation of or expected changes in concomitant medication that may affect psoriasis vulgaris (e.g., beta blockers, anti-malaria drugs, lithium and ACE inhibitors) during the study
  • Systemic treatment with vitamin D preparations above 500 IU per day
  • Current diagnosis of erythrodermic, exfoliative, guttate or pustular psoriasis
  • Patients with any of the following conditions present on the treatment area: viral (e.g., herpes or varicella) lesions of the skin, fungal and bacterial skin infections, parasitic infections, skin manifestations in relation to syphilis or tuberculosis, rosacea, perioral dermatitis, acne vulgaris, atrophic skin, striae atrophicae, fragility of skin veins, ichthyosis, acne rosacea, ulcers and wounds
  • Other inflammatory skin diseases (e.g., seborrhoeic dermatitis, contact dermatitis and cutaneous mycosis) that may confound the evaluation of psoriasis vulgaris on the face or on the intertriginous areas
  • Planned exposure to sun, UVA or UVB that may affect the psoriasis vulgaris during the study
  • Known or suspected severe renal insufficiency or severe hepatic disorders
  • Known or suspected disorders of calcium metabolism associated with hypercalcemia

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00640822


Locations
Canada, Ontario
Probity Medical Research
Waterloo, Ontario, Canada, N2J1C4
France
Hôpital de l'Archet
Nice, France, 06202
United Kingdom
Ninewells Hospital & Medical School
Dundee, United Kingdom, DD1 9SY
Sponsors and Collaborators
LEO Pharma
Investigators
Principal Investigator: Colin Fleming, MD Ninewells Hospital & Medical School

Responsible Party: LEO Pharma
ClinicalTrials.gov Identifier: NCT00640822     History of Changes
Other Study ID Numbers: LEO 80190-O22
First Posted: March 21, 2008    Key Record Dates
Results First Posted: December 21, 2010
Last Update Posted: April 29, 2015
Last Verified: April 2015

Additional relevant MeSH terms:
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases
Hydrocortisone 17-butyrate 21-propionate
Hydrocortisone acetate
Cortisol succinate
1 alpha,24-dihydroxyvitamin D3
Hydrocortisone
Calcipotriene
Calcitriol
Dihydroxycholecalciferols
Anti-Inflammatory Agents
Dermatologic Agents
Calcium Channel Agonists
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Vasoconstrictor Agents
Vitamins
Micronutrients
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents